INT26492

From wiki-pain
Revision as of 10:18, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1980
Last Reported 2010
Negated 1
Speculated 2
Reported most in Body
Documents 73
Total Number 75
Disease Relevance 22.20
Pain Relevance 9.48

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (GCG) signal transduction (GCG) extracellular space (GCG)
small molecule metabolic process (GCG) extracellular region (GCG) plasma membrane (GCG)
Anatomy Link Frequency
blood 4
adipose tissues 3
plasma 2
alpha cells 2
brain 2
GCG (Homo sapiens)
Pain Link Frequency Relevance Heat
Somatostatin 335 100.00 Very High Very High Very High
gABA 175 100.00 Very High Very High Very High
Clonidine 16 100.00 Very High Very High Very High
Serotonin 9 100.00 Very High Very High Very High
epidural 1 100.00 Very High Very High Very High
conotoxin 420 99.68 Very High Very High Very High
tetrodotoxin 350 99.48 Very High Very High Very High
agonist 213 99.14 Very High Very High Very High
tolerance 94 99.00 Very High Very High Very High
Catecholamine 10 98.84 Very High Very High Very High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 1683 100.00 Very High Very High Very High
Hypoglycemia 780 100.00 Very High Very High Very High
Gastric Motility Disorder 12 99.80 Very High Very High Very High
Insulin Resistance 79 99.24 Very High Very High Very High
Appetite Loss 15 99.04 Very High Very High Very High
Impaired Glucose Tolerance 90 99.00 Very High Very High Very High
Pancreatitis 203 98.68 Very High Very High Very High
Hyperglycemia 73 98.04 Very High Very High Very High
Hepatotoxicity 10 97.88 Very High Very High Very High
Insulinoma 25 97.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Defective glucagon secretion during hypoglycemia is characteristic of long-standing type I diabetes.
Negative_regulation (Defective) of Localization (secretion) of glucagon associated with hypoglycemia and diabetes mellitus
1) Confidence 0.58 Published 1997 Journal Diabetes Section Abstract Doc Link 8971076 Disease Relevance 0.56 Pain Relevance 0.08
Defective glucagon secretion during sustained hypoglycemia following successful islet allo- and autotransplantation in humans.
Negative_regulation (Defective) of Localization (secretion) of glucagon associated with hypoglycemia
2) Confidence 0.58 Published 1997 Journal Diabetes Section Title Doc Link 8971076 Disease Relevance 0.74 Pain Relevance 0.09
This is mainly caused by the impaired glucagon secretion but also influenced by malnutrition and concomitant hepatic dysfunction due to the toxic affect of alcohol.
Negative_regulation (impaired) of Localization (secretion) of glucagon associated with appetite loss, hepatotoxicity and alcohol
3) Confidence 0.57 Published 1999 Journal Z Gastroenterol Section Abstract Doc Link 10444809 Disease Relevance 1.30 Pain Relevance 0.51
Heterotopic pancreas transplantation in type I diabetic patients does not correct hyperglucagonemia, which is thought to be due to insufficiently suppressed glucagon release by the host pancreas.
Negative_regulation (suppressed) of Localization (release) of glucagon in pancreas associated with diabetes mellitus
4) Confidence 0.57 Published 1999 Journal Res Exp Med (Berl) Section Abstract Doc Link 10550640 Disease Relevance 0.18 Pain Relevance 0
M diazoxide) relieved the suppression of glucagon secretion from both mouse (Figure 2A) and rat (Figure 2B) islets.
Negative_regulation (suppression) of Localization (secretion) of glucagon
5) Confidence 0.46 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.03
-conotoxin), but not L-type Ca2+ channels (nifedipine), prevented glucagon secretion.
Negative_regulation (prevented) of Localization (secretion) of glucagon associated with conotoxin
6) Confidence 0.46 Published 2007 Journal PLoS Biology Section Abstract Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.12
Similar to above, glucagon secretion from human islets was suppressed by 58 ± 3% (n = 9, p < 0.05) upon raising the glucose concentration from 0 to 10 mM.
Negative_regulation (suppressed) of Localization (secretion) of glucagon
7) Confidence 0.46 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0
At low-glucose concentrations, glucagon secretion from the Kir6.2Y12X islets was already suppressed compared with that from wild-type islets (Figure 3B), similar to the effect of glucose stimulation or pharmacological KATP channel inhibition observed in Figures 2D and 3A.
Negative_regulation (suppressed) of Localization (secretion) of glucagon
8) Confidence 0.46 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.03
cells, but in agreement with the conclusion of Ostenson et al. [54], that sulfonylureas can inhibit glucagon secretion by a direct, non-paracrine mechanism.
Negative_regulation (inhibit) of Localization (secretion) of glucagon
9) Confidence 0.46 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.09
M) inhibited glucagon release by 43 ± 14% (n = 7, p < 0.05).
Negative_regulation (inhibited) of Localization (release) of glucagon
10) Confidence 0.46 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0
The mechanism underlying this switch in Ca2+ channel dependence remains obscure, but may depend on the strength of depolarisation because glucagon secretion stimulated by strong depolarisation with increased K+ in combination with KATP channel block can be prevented by inhibition of L-type Ca2+ channels [47].
Negative_regulation (prevented) of Localization (secretion) of glucagon associated with addiction
11) Confidence 0.46 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0.14 Pain Relevance 0.12
Thus, although the present data do not entirely rule out these pathways as modulators of glucagon secretion, glucose is clearly able to suppress glucagon secretion independently of these.

?

Negative_regulation (suppress) of Localization (secretion) of glucagon
12) Confidence 0.46 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.20
Although insulin secretion in homozygous Glu23Lys individuals was not different from controls, glucose-induced suppression of glucagon release was blunted [29].
Negative_regulation (suppression) of Localization (release) of glucagon
13) Confidence 0.46 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0.08 Pain Relevance 0
Thus, glucose likely leads to the suppression of glucagon secretion by depolarising the ?
Negative_regulation (suppression) of Localization (secretion) of glucagon
14) Confidence 0.46 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.04
These data indicate that in man clonidine-induced GH secretion is not mediated by a stimulatory effect of clonidine on glucagon secretion and that alpha-adrenergic mechanisms have little role in the regulation of basal glucagon secretion.
Negative_regulation (effect) of Localization (secretion) of glucagon associated with clonidine
15) Confidence 0.42 Published 1981 Journal Horm. Metab. Res. Section Abstract Doc Link 7308974 Disease Relevance 0 Pain Relevance 0.36
Finally, inhibitors of pancreatic secretion including somatostatin, calcitonin and glucagon showed no protective effect for PEP, yet maybe octreotide and beta-carotine administration had a beneficial effect.
Negative_regulation (inhibitors) of Localization (secretion) of glucagon associated with pancreatitis and somatostatin
16) Confidence 0.42 Published 2010 Journal BMC Gastroenterol Section Body Doc Link PMC2921391 Disease Relevance 0.54 Pain Relevance 0.34
Glucagon secretion was not impaired, but CLON blunted the early rate of glucose recovery in the first 15 min after the glucose nadir.
Negative_regulation (impaired) of Localization (secretion) of Glucagon associated with clonidine
17) Confidence 0.42 Published 1980 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 6996898 Disease Relevance 0.32 Pain Relevance 1.08
Importantly, in the presence of a maximally inhibitory tolbutamide concentration (0.5 mM), glucose was unable to produce any further inhibition of glucagon release (Figure 3A).
Negative_regulation (inhibition) of Localization (release) of glucagon
18) Confidence 0.40 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1868042 Disease Relevance 0 Pain Relevance 0.04
For example, food intake will promote insulin release, which will in turn increase formation of glycogen stores, facilitate glucose uptake in muscle and adipose tissues, and suppress hepatic glucose output, in part via paracrine suppression of glucagon release.
Negative_regulation (suppression) of Localization (release) of glucagon in adipose tissues
19) Confidence 0.37 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597758 Disease Relevance 0.56 Pain Relevance 0
GLP-1 (secreted by L cells of the small intestine) has a variety of effects on glucose homeostasis, including regulation of gastric emptying; the stimulation of insulin secretion in a glucose-dependent fashion; and the suppression of glucagon secretion (Drucker 2003).
Negative_regulation (suppression) of Localization (secretion) of glucagon in small intestine
20) Confidence 0.37 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597758 Disease Relevance 0.31 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox